{"id":391679,"date":"2014-04-18T00:00:00","date_gmt":"2014-04-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0614-biopharma-nsclc-egfr-mutation-positive-previously-treated-decisionbase-us-eu-2014\/"},"modified":"2026-03-31T09:05:28","modified_gmt":"2026-03-31T09:05:28","slug":"dbason0614-biopharma-nsclc-egfr-mutation-positive-previously-treated-decisionbase-us-eu-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0614-biopharma-nsclc-egfr-mutation-positive-previously-treated-decisionbase-us-eu-2014\/","title":{"rendered":"NSCLC (EGFR-Mutation-Positive; Previously Treated) | DecisionBase | US\/EU | 2014"},"content":{"rendered":"<p><em>Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy?<\/em><\/p>\n<p>Treatment decisions for non-small-cell lung cancer (NSCLC) patients are increasingly based on personalized tumor-specific characteristics. It is now standard practice for patients with advanced NSCLC of nonsquamous-cell\u2014particularly adenocarcinoma\u2014histology to undergo testing for epidermal growth factor receptor (EGFR) mutations. While the first-generation EGFR tyrosine kinase inhibitors (TKIs), erlotinib (Genentech\/Roche\/Chugai\/Astellas\u2019s Tarceva) and gefitinib (AstraZeneca\u2019s Iressa) have revolutionized the first-line treatment of NSCLC (<em>EGFR<\/em>-mutation-positive; previously treated), no targeted agents are currently approved in the second or subsequent- lines. Consequently, the outcome for patients with NSCLC (<em>EGFR<\/em>-mutation-positive; previously treated) remains bleak. Going forward, the market is expected to become increasingly competitive following the approval of the targeted second-generation and third-generation EGFR TKIs for NSCLC (<em>EGFR<\/em>-mutation-positive; previously treated). Despite this development, significant clinical and commercial opportunity remains for therapies that can provide greater survival benefits than current standards of care.<\/p>\n","protected":false},"template":"","class_list":["post-391679","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391679\/revisions"}],"predecessor-version":[{"id":394802,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391679\/revisions\/394802"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}